Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial — Shunya Ikeda (2021) | RDL Network
Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial
Richard S. Finn, Shukui Qin, Fabio Piscaglia, T.R. Jeffry Evans, Jennifer J. Knox, Carlos López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.